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ABSTRACT 
Objective: To evaluate the  activity and safety of adding oxaliplatin to a  standard chemoradiotherapy schema, 
including 5-fluorouracil (5-FU)/folinic acid (FA), in locally-advanced rectal cancer (LARC). 
Methods:  Two  cycles  of  oxaliplatin  130 mg/m
2  plus  FA  20 mg/m
2  bolus  for  5  days  and  5-FU  350 mg/m
2 
continuous infusion for 5 days were given during week 1 and 4 of pelvic radiotherapy 46 Gy. Patients with a T3/4 and/or 
node-positive rectal tumour were eligible. Surgery was performed 4–6 weeks after radiotherapy. The primary endpoint 
was to determine the rate of pathological response. Secondary endpoints were to assess the rate of clinical response and 
the safety profile. 
Results: Between March 2005 and January 2009, a total of 35 patients were enrolled. The pathological down-
staging rate was 79% with a pathological complete response rate of 17%. The overall clinical response rate (assessed by 
computed tomography or transrectal ultrasound) was 77%. Grade 3 diarrhoea and Grade 3 neutropaenia were reported in 
14% and 11% of the patients, respectively. Eleven patients did not undergo surgery: four of them refused the operation, 
and seven patients were inoperable due to disease progression. In 24 patients who had surgery, a sphincter-preserving 
procedure could be performed in 29%. At the median follow-up time of 28.1 months, 25 patients (71%) survived with no 
evidence of disease. 
Conclusion: The promising results in terms of pathological response, and the associated good safety profile of a 
regimen of oxaliplatin plus 5-FU/FA with concomitant radiotherapy, suggest that the regimen could be used in LARC. 
© 2011 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Colorectal cancer (CRC) is the third most common 
cancer in males and the fifth most common cancer in 
females  in  Thailand.  Its  estimated  incidence  rate  in 
Thailand is 8.8 for males and 7.6 for females [1], with 
more than 8,000 new CRC patients reported in 2008
 [2]. 
In Thailand, because of socioeconomic problems and 
healthcare  disparities,  patients  not  included  in  the 
medical  care  system  frequently  have  large  tumour 
volumes and are diagnosed at an advanced stage. For 
example,  of  cases  with  known  stage  in  Chiang  Mai, 
only  10.4%  were  diagnosed  with  localised  disease, 
whereas 29.2% had metastatic disease [1]. Progression 
of  locally-advanced  disease,  with  or  without  distant 
metastasis, leads to the disabling symptoms and high 
mortality associated with unresectable rectal cancer [3]. 
Hence,  early  and  aggressive  management  of  CRC  is 
warranted  for  locoregional  control  and  palliation  of 
symptoms. 
5-fluorouracil  (5-FU)  has  been  the  mainstay  of 
chemotherapy for CRC for almost 40 years [4], and is 
used  both  in  adjuvant  and  palliative  settings  [5].  A 
number of biochemical modulators have been used in 
combination  with  5-FU  in  an  attempt  to  improve  its 
efficacy while maintaining acceptable toxicity. Among 
them, the most successful to date is folinic acid (FA; 
also called leucovorin [LV]) [6, 7], and regimens based 
on  5-FU + FA  have  become  standard  in  many 
institutions worldwide. 
Oxaliplatin  is  a  third-generation  platinum 
derivative, which, when combined with 5-FU and LV, 
is  among  the  most  effective  chemotherapies  for 
metastatic CRC [5, 8–10]. In a pivotal phase III study, 
the addition of oxaliplatin to 5-FU plus FA doubled the 
response  rate  (RR)  and  prolonged  progression-free 
survival  among  patients  with  metastatic  CRC  [5]. 
Oxaliplatin is registered in Europe and in the USA for 
the  treatment  of  advanced  or  metastatic  CRC,  in 
combination  with  5-FU  and  FA/LV.  The  indication 
encompasses both first and second -line treatment. 
In  the  treatment  of  rectal  cancer,  concurrent 
chemoradiation with 5-FU improves both local control 
and  overall  survival  (OS)  when  compared  with 
radiotherapy  (RT)  alone.  Thus,  combined-modality 
treatment has been accepted as an integral part of the 
pre- and post-operative treatment of rectal cancer [11, 
12]. In a randomised German study comparing pre- and 
post-operative 5-FU concurrent with radiation in rectal 
cancer,  no  significant  differences  between  the  two 
approaches  were  reported  in  terms  of  OS.  However, 
treatment compliance, grade 3/4 toxicity, tumour down-
staging,  rate  of  sphincter  preservation  and  rates  of 
pelvic  recurrence  all  favoured  the  pre-operative 
chemoradiation  arm  [13].  Thus,  preoperative 
chemoradiotherapy  (CRT)  is  clearly  preferred  when 
tumour shrinkage is required before surgery, that is, in 
locally-advanced  T4  disease  and  low-lying  tumours 
when sphincter preservation is attempted [13–15]. 
At present, in patients with locally-advanced rectal 
cancer  (LARC),  pre-operative  CRT  is  the  standard 
treatment, with 5-FU ± folinic acid being the standard 
chemotherapy regimen concurrent with RT. Oxaliplatin 
is  an  ideal  candidate  for  inclusion  in  CRT  regimens 
because  of  its  radiosensitising  capabilities,  synergy 
with  fluoropyrimidines  [16],  and  its  relative  lack  of 
acute dose-limiting adverse effects when added to RT 
and  5-FU  [17]. Phase  I  studies  showed  pre-operative 
radiation concurrent with oxaliplatin and 5-FU/FA was 
well-tolerated in patients with rectal cancer
 [18]. Hence, 
based on this evidence, oxaliplatin combined  with 5-
FU/FA  was  chosen  as  the  chemotherapy  regimen 
concomitant with pre-operative radiation in this phase 
II clinical trial to test the activity and feasibility of this 
new pre-operative treatment in LARC. 
The primary objective of this study was to assess 
the  RR  of  concurrent  pre-operative  chemotherapy 
(oxaliplatin/5-FU/FA)  plus  radiation  in  patients  with 
LARC.  The  secondary  objective  was  to  assess  the 
safety profile and disease-free survival (DFS). 
METHODS 
Study Design 
This was a prospective, single-centre, open-labeled, 
phase II study carried out at Chiang Mai University in 
Thailand.  The  study  was  conducted  according  to 
globally-accepted standards of Good Clinical Practice, 
and  in  agreement  with  the  latest  revision  of  the 
Declaration  of  Helsinki  and  local  regulations.  The 
planned duration of the entire study was 4 years. It was 
planned to enroll a total of 30 patients during the study 
period  of  18  months.  All  eligible  patients  were 
registered prior to the start of treatment and treatment 
was started no later than 8 days after registration. 
Pre-operative  RT  was  given  for  a  period  of  5 
weeks. Chemotherapy was administered synchronously 
on week 1 and 5 of radiation. After the end of treatment, 
patients  were  scheduled  for  surgery  4–6  weeks  after 
completion of concurrent CRT. Post-operative patients 
received  adjuvant  chemotherapy  on  the  discretion  of 
the  investigator.  Patients  were  followed  up  every  3 
months  up  to  2  years  or  death,  whichever  occurred 
earlier. 
Treatment  could  be  discontinued  before  the 
completion  of  treatment  for  the  following  reasons: 
progression  of  disease,  serious  adverse  events  (AEs) 
including inter-current illness and unacceptable toxicity 
which renders further treatment on protocol detrimental 
to  thepatient,  delay  of  more  than  2  weeks  for  blood 
counts to recover or for non-haematological toxicities 
to improve to Grade 2 or less, at the discretion of the 
managing physician, at request from the patient, or due 
to death or loss to follow-up. 
Study Population 
Adult  patients  (between  20  and  70  years)  with 
histologically proven, locally-advanced (T3-4/N1-3/M0) 
adenocarcinoma  of  the  rectum,  with  a  measurable Chitapanarux et al. Biomed Imaging Interv J 2011; 7(4):e25    3 
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lesion, Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) of ≤ 2 and life expectancy of 
more than 6 months were included in the study, if they 
had  had  no  prior  specific  treatment  for  rectal  cancer 
except  biopsy,  had  adequate  haematological  function 
(haemoglobin  ≥ 10 g/dL,  absolute  neutrophil  count 
(ANC)  ≥ 1.5 × 10
9/L  and  platelets  ≥ 100 × 10
9/L),  as 
well  as  adequate  renal  and  hepatic  functions  (total 
bilirubin ≤ 1.25 × upper normal limits; SGOT, SGPT 
and  alkaline  phosphatase  ≤ 3  ×  upper  normal  limits; 
and  creatinine  ≤ 1  ×  upper  normal  limits).  Other 
inclusion  criteria  included  the  ability  to  comply  with 
scheduled follow-up and with management of toxicity, 
signed  informed  consent  from  the  patient  or  legal 
representative  and  negative  urine  pregnancy  test  (if 
indicated). 
Patients were excluded from the study if they had 
metastatic  rectal  cancer,  other  tumour  types  than 
adenocarcinoma  of  the  rectum,  were  pregnant  or 
lactating, or  were  with reproductive potential but not 
implementing adequate contraceptive measures. Other 
exclusion criteria were: current uncontrolled infection; 
unresolved  bowel  obstruction  or  subobstruction; 
uncontrolled  Crohn's  disease  or  ulcerative  colitis; 
current  history  of  chronic  diarrhoea;  other  serious 
illness or medical conditions; contraindication towards 
experimental  drugs  and  radiation;  past  or  concurrent 
history of neoplasm other than rectal adenocarcinoma, 
except curatively treated non-melanoma skin cancer or 
in  situ  carcinoma  of  the  cervix;  concurrent  treatment 
with any other anti-cancer therapy; or administration of 
any  other  experimental  drug  under  investigation 
concomitantly or within 4 weeks before eligibility. 
Evaluations Prior to Enrolment and During the Study 
History  and  physical  examination,  assessment  of 
performance status, weight, complete blood count, liver 
function  test,  blood  urea  nitrogen  (BUN),  creatinine 
and  pregnancy  test  (if  indicated)  were  carried  out 
within 7 days prior to enrolment. Chest x-ray and CT 
scan of the whole abdomen for evaluation were done 
within 4 weeks prior to enrolment. Bone scan and CT 
scan of other parts (if clinically indicated) for exclusion 
of distant metastases were done within 4 weeks prior to 
enrolment. 
History and physical examination including weight, 
Performance Status (PS) and vital signs were done on 
the first day of each week of radiation. Laboratory tests 
for full blood counts, BUN and creatinine were done on 
the  first  day  of  each  week  of  radiation.  Physical 
examinations and imaging studies were done 4 weeks 
after completion of radiation to assess clinical response. 
Toxicity of treatment was assessed during each clinic 
visit  using  the  National  Cancer  Institute  Common 
Toxicity  Criteria  (NCI-CTC)  version  2.  History, 
physical examination and late toxicity assessment using 
Radiation  Therapy  Oncology  Group  (RTOG)  toxicity 
criteria were done during each follow-up visit. 
Study Treatment 
All  patients  whomet  the  eligibility  criteria 
underwent treatment with pre-operative chemoradiation. 
The treatment schema is shown in Figure 1. 
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Figure 1 Disease-free survival  
 
Pre-operative evaluation for surgery 
All  eligible  patients  were  evaluated  for  the 
planning  of  surgery  before  starting  the  treatment 
(between  abdomino-perineal  resection  and  sphincter-
sparing surgery), and were recorded into the patient’s 
chart by surgeons. 
Chemotherapy 
Two  cycles  of  chemotherapy  were  given 
synchronously  on  week  1  and  5  of  radiation. 
Chemotherapy  regimen  started  with  oxaliplatin  at  a 
dose  of  130 mg/m
2  administered  as  a  120-minute 
intravenous (i.v.) infusion on day 1 followed by FA at 
dose  of  20 mg/m
2  i.v.  bolus  and  5-FU  350 mg/m
2 
continuous  infusion  on  day  1–5  of  each  cycle.  Anti-
emetic  drugs  were  given  on  the  discretion  of  the 
investigator before and after chemotherapy infusion in 
order  to  prevent  or  palliate  chemotherapy-induced 
nausea and vomiting. 
Dose  reduction  was  planned  in  case  of  severe 
haematological  and/or  non-haematological  toxicities. 
Dose adjustments were made according to the system 
showing the greatest degree of toxicity. Toxicities were 
graded using the NCI-CTC version 2. If the ANC was 
< 1.5 × 10
9/L,  platelet  count  was  < 100 × 10
9/L,  and 
diarrhoea  and  mucositis  were  NCI  Grade  > 1,  the 
chemotherapy  infusion  was  delayed  until  ANC 
recovered  to  ≥ 1.5 × 10
9/L,  platelet  count  was 
≥ 100 × 10
9/L and diarrhoea and mucositis were of NCI 
Grade ≤ 1. If the ANC was ≤ 0.5 × 10
9/L (or if it was 
≤ 1.0 × 10
9/L  in  the  presence  of  a  fever  /  infection), 
platelet  count  was  < 25 × 10
9/L,  and  diarrhoea  and 
mucositis were of NCI Grade 3 or 4, chemotherapy was 
delayed  until  the  ANC  recovered  to  ≥ 1.5 × 10
9/L, 
platelet  count  was  ≥ 100 × 10
9/L,  and  diarrhoea  and 
mucositis  were  of  NCI  Grade  ≤ 1.  Thereafter,  the 
infusion was given with 20% reduction in doses, i.e., 5-Chitapanarux et al. Biomed Imaging Interv J 2011; 7(4):e25    4 
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FU 280 mg/m
2 and oxaliplatin 100 mg/m
2. Doses that 
were  once  reduced  because  of  toxicity  were  not  re-
escalated. 
Radiation 
Pre-operative  RT  (whole  pelvic  RT)  was  given 
with  linear  accelerator  machine.  Treatment  field 
consisted  of  anterior-posterior  or  four-field  box 
technique. Conventional dose RT (200 cGy/d) was used 
with total tumour dose of 5,000 cGy in 5 weeks. 
If  the  ANC  was  < 1.5 × 10
9/L  and  platelet 
count was < 100 × 10
9/L, RT was delayed for 
1 week. If RT was delayed, chemotherapy was 
also delayed. The interval between doses was 
recorded.  For  patients  who  developed 
 Grade 3 radiation proctitis, RT was delayed 
until the toxicity level was  Grade 2. If the 
ANC  was  < 1.5 × 10
9/L,  but  the  platelets 
were  > 100 × 10
9/L,  the  continuing  of 
radiation  was  on  the  discretion  of  the 
investigator. 
Prior and concomitant treatments 
Every drug prescribed to the patients was recorded 
in  the  appropriate  space  on  the  case  record  forms. 
Symptomatic treatments were permitted, including any 
specific medication (except anti-cancer drugs) justified 
for any medical indication including cancer symptoms 
and side effects of  study drugs. The patients did  not 
receive  other  investigational  drugs  and  anti-cancer 
treatment while on treatment. 
Study Assessments 
Pathological response 
The  tumour  site  was  entirely  sectioned  for 
pathological  examination  of  the  response  of 
preoperative  treatment.  The  viable  tumour  cells  were 
documented as residual disease. Residual tumour was 
staged  according  to  the  2002  AJCC  Staging. 
Pathological complete response (pCR) was defined by 
the complete absence of tumour cells from the entire 
specimen. 
Clinical response 
Transrectal  ultrasound  and  CT  were  performed 
prior  to  surgery.  Measurable  lesions  were  measured 
using  the  longest  diameters  of  the  lesions.  Response 
was  evaluated  according  to  the  Response  Evaluation 
Criteria In Solid Tumors Group (RECIST) criteria at 4 
weeks  after  complete  radiation.  The  same  method  of 
assessment  and  the  same  technique  was  used  to 
characterise  each  identified  and  reported  lesion  at 
baseline and during follow-up. 
Disease-free survival 
Follow-up  continued  at  every  3  months  after 
surgery for up to 2 years or death, whichever occurred 
earlier.  Hence,  the  time  measured  from  the  day  of 
eligibility to the first recurrence or death was analysed 
as DFS. Kaplan-Meier curve was plotted. 
Safety profile 
The following tests were performed prior to and/or 
on specified days during and following therapy: history 
of malignant and non-malignant diseases; full clinical 
examination,  height,  weight,  assessment  of  residual 
toxicity  due  to  prior  therapy  and  disease  symptoms 
according to NCI-CTC version 2, and PS according to 
ECOG criteria; and complete blood count. 
Each patient  was regularly assessed for potential 
AEs and disease-related signs and symptoms according 
to the NCI-CTC version 2. If not applicable, the event 
was  graded  as  1 = mild,  2 = moderate,  3 = severe, 
4 = life-threatening. All events, even not related, were 
reported. 
Withdrawal  from  the  study  and  therapeutic 
measures were at the discretion of the investigator. A 
full explanation for the treatment discontinuation from 
the study was made on the appropriate case record form. 
Statistical Methods 
Sample size 
The main objective of this trial was to assess the 
clinical RR of concurrent pre-operative chemotherapy 
(oxaliplatin/5FU/FA) plus radiation in LARC. A RR of 
60% was considered as the minimum activity level of 
interest,  while  a  RR  of  75%  was  promising.  With 
respect to these considerations, the two-stage method of 
Simon’s  Optimal  Design  was  used  to  estimate  the 
sample  size.  The  parameters  used  were  p(0) = 0.60, 
p(1) = 0.75, beta = 0.20, and alpha = 0.05. The sample 
size was calculated to be 30. 
Statistical analyses 
All  untreated  patients  were  described  separately 
and the reasons they did not receive the treatment were 
given.  The  evaluable  population  consisted  of  eligible 
patients (with  no  major protocol violations)  who had 
received  at  least  one  complete  cycle  of  treatment. 
However, if a progression occurred before the end of 
the first cycle, the patient was considered as evaluable 
(early progression). 
For  the  efficacy  analysis,  RR,  and  DFS  were 
estimated.  The  RR,  with  its  95%  confidence  interval 
(using  binomial  estimation),  was  calculated  on  the 
evaluable population. DFS was analysed on the intent-
to-treat (ITT) population. 
Safety  analysis  of  the  population  receiving 
treatment  included  analysis  of  AEs  according  to  the 
relationship  with  the  treatment,  the  severity  and 
seriousness. Analysis by patient was provided. Chitapanarux et al. Biomed Imaging Interv J 2011; 7(4):e25    5 
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Table 1 Baseline Characteristics. 
 
Characteristic  Value 
Age, years   
Median  54 
Range  20-70 
Sex, n (%)   
Male  20 (57.14) 
Female  15 (42.86) 
Distance between the lower margin of the tumour and the dentate line, cm   
Median  5 
Range  1-13 
Eastern Cooperative Oncology Group performance status, n (%)   
0  30 (85.71) 
1  5 (14.29) 
Clinical stage (as detected by transrectal ultrasound), n (%)   
T3N0  12 (34.29) 
T3N+  17 (48.57) 
T4N0  3 (8.57) 
T4N+  3 (8.57) 
Planned surgery, n (%)   
Abdominoperineal resection  30 (85.71) 
Low anterior resection  5 (14.29) 
 
Table 2 Response Rates. 
 
Response 
Patients In Whom Definitive Surgery 
Was Performed
1 
Patients In Whom Definitive Surgery Was 
Not Performed
2 
Complete Response   4  0 
Partial Response  19  4 
Stable Disease  1  0 
Progressive Disease  0  7 
1 response based on histopthologic assessment 
2 response based on endoscopic ultrasound or CT examination 
RESULTS 
Patient Characteristics 
A total of 35 patients were enrolled in the study 
between March 2005 and January 2009. Their baseline 
characteristics are presented in Table 1. 
Response Rates 
After pre-operative  CRT, surgery  was performed 
in 24 (69%) of 35 patients. The median interval from 
completion of radiotherapy to surgery was 6.2 weeks 
(range  5.5–7.5).  Of  these,  17  (71%)  underwent 
abdominoperineal  resection  (APR),  whereas  7  (19%) 
underwent low anterior resection (LAR). Surgery was 
not performed in 11 (31%) patients: in 7 cases due to 
disease progression and unresectable tumour and in 4 
cases due to patient refusal. Sphincter preservation rate 
was 29%. 
Clinical Response Rates 
In  the  intention  to  treat  population  (n = 35),  27 
patients  (77%)  had  objective  response  (4  complete 
response;  CR  and  23  partial  response;  PR),  and  7 
patients  (20%)  had  progressive  disease;  PD.  Among 
patients with PD, metastases were found in the liver in 
2 cases, in the small bowel in 2 cases, in the bladder in 
2 cases, and there was peritoneal seeding in 1 case. Chitapanarux et al. Biomed Imaging Interv J 2011; 7(4):e25    6 
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Table 3 Common Haematological Toxicity (NCI-CTC v 2.0) (n=35) 
 
Haemato-toxicity  Grade 1 
n (%) 
Grade 2 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Leucopaenia  4 
(11) 
1 
(3) 
4 
(11) 
- 
Thrombocytopaenia  1 
(3) 
1 
(3) 
-  - 
Anaemia  1 
(3) 
2 
(6) 
-  - 
 
Table 4 Common Non-Haematological Toxicity (NCI CTC v 2.0) (n=35) 
 
Non-haematological Toxicity  Grade 1 
n (%) 
Grade 2 n (%)  Grade 3 
n (%) 
Grade 4 
Diarrhoea  1(3)  2(6)  5 (14)  - 
Nausea -vomiting  5(14)  -  -  - 
Peripheral neuropathy  1(3)  -  -  - 
 
Pathological Response Rates 
Of the 35 patients enrolled, 24 underwent surgery 
and  the  pathological  response  rate  is  presented  in 
Table 2.  Four  in  24  patients  (17%)  had  pathological 
complete response, while 19 out of 24 patients (79%) 
had  pathological  partial  response.  One  patient  had 
pathological stable disease. 
Toxicity 
The safety of the regimen was evaluated in all 35 
patients. The regimen was well tolerated. 
Diarrhoea  was  the  most  common  non- 
haematologic toxicity (14%). RT was completed to the 
planned dose of 50 Gy. However, only one patient (3%) 
received  delayed in the RT treatment due to grade 3 
ANC. Chemotherapy was also delayed in this patient. 
Grade 3 leucopaenia was found in 11%. All the cases 
received 2 cycles of chemotherapy with RT. No grade 4 
toxicity  was  seen  during  chemoradiation.  Details  are 
presented  in  Tables 3  and  4.  There  were  no  deaths 
related to toxicity during chemoradiation. No surgical 
morbidity was reported in 24 patients who underwent 
surgery. 
Follow up 
The median follow-up duration  was 28.1 months 
(range: 8–48.1 months). At the time of analysis in May 
2010,  there  was  no  evidence  of  disease  in  25  (71%) 
patients,  9  patients  (26%)  were  living  with  disease, 
while 1 patient (3%) was dead. 
DISCUSSION 
In  this  phase  II  study  to  assess  the  activity  and 
feasibility of oxaliplatin + 5-FU/FA concomitant with 
preoperative  RT  in  LARC,  the  overall  clinical  RR 
(assessed  by  CT  or  transrectal  ultrasound)  was  77%. 
The  pathological  down-staging  rate  was  79%, 
indicating good efficacy of the study regimen. Thus, the 
regimen  of  oxaliplatin  + 5-FU/FA  concomitant  with 
pre-operative  RT  was  found  to  be  active  in  patients 
with LARC. It was also quite well-tolerated, and hence 
is a feasible chemotherapy regimen to be used in pre-
operative combined-modality treatment. 
The addition of oxaliplatin to standard CRT seems 
to  be  associated  with  a  high  pathological  CR  (pCR) 
[19].  Pathological  CR  is  a  reliable  and  reproducible 
surrogate  for  tumour  response  and  is  linked  to 
improved outcome [20, 21]. Although achievement of a 
pCR is not the primary goal of neoadjuvant therapy, it 
has become a commonly used endpoint in many phase 
II trials aiming to improve the efficacy of rectal cancer 
treatment [16]. A pCR between 10% and 30% has been 
observed  with  combined  pre-operative  chemotherapy 
and RT protocols [16]. In several phase II trials of 5-FU, 
LV  and  oxaliplatin  in  pre-operative  CRT,  a  pCR  of 
14% to 19% was reported [22–24]. The pCR of 17% 
observed  in  this  reported  study  is  in  line  with  other 
studies using oxaliplatin + 5-FU/FA concomitant with 
RT. 
Diarrhoea (14%) and leucopaenia (11%) were the 
only toxicities of Grade 3. No toxicity of Grade 4 was 
reported.  Single-centre  or  limited  institutional  studies Chitapanarux et al. Biomed Imaging Interv J 2011; 7(4):e25    7 
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evaluating  the  combination  of  oxaliplatin  and  a 
fluoropyrimidine  with  RT  for  patients  with  rectal 
cancer  have  not  reported  high  toxicity  rates  [19].  In 
several phase II trials of 5-FU, LV and oxaliplatin in 
pre-operative CRT, Grade 3/4 diarrhoea was observed 
in 8% to 30% patients. [22–24] Grade 3/4 leucopaenia 
was reported in 9% patients [23]. Hence, the toxicity 
profile  of  our  study  regimen  was  similar  to  that 
reported in other CRT regimens of 5-FU/LV/oxaliplatin. 
Comparing  these  results  with  the  results  of  5-FU 
concurrently to radiotherapy , there were no differences 
in efficacy and toxicity (grade 3 or more toxicity: 15–
25%) [14, 15]. However, the incidence of acute toxicity 
during  concurrent  capecitabine  and  radiotherapy  was 
lower than our results, and grade 3 toxicity was found 
in only 8–11% [16, 25]. 
After  a  median  follow-up  of  28.1  months,  there 
was no evidence of disease in 71% of the patients. The 
2-year  disease-free  survival  was  74.9%,  as  shown  in 
Figure 1. Adverse effects due to RT, such as defecation 
problems, occurred after a longer follow-up period [25]. 
The RR, or downsizing or down-staging as it can 
be  analysed  on  the  operative  specimen,  is  a  good 
endpoint to evaluate the efficacy of a pre-operative RT 
or CRT approach [26]. This endpoint heavily depends 
on  the  pathologic  technique  used  to  analyse  the 
operative  specimen.  The  rate  of  pCR  also  closely 
depends on the number of sections performed and the 
quality  of  search  for  residual  cancer  cells.  The 
definition  of  viable  cells  can  also  be  a  source  of 
discrepancy [22]. 
In  conclusion,  the  good  safety  profile  of  the 
regimen  of  oxaliplatin  + 5-FU/FA  concomitant  with 
pre-operative RT, associated with promising results in 
terms  of  pathological  response,  suggests  that  the 
regimen  could  be  used  in  LARC  and  developed  in 
future multi-centre phase III studies involving a larger 
study population. 
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